Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes

Background. The aims of this study were (1) to examine the renoprotective effects of alogliptin and (2) to establish urinary angiotensinogen (AGT) as a prognostic marker of renoprotective effects of alogliptin in patients with type 2 diabetes (T2D). Methods. In 43 patients with T2D (18 women, 66.1±1...

Full description

Saved in:
Bibliographic Details
Main Authors: Tomoko Mizushige, Hiroyuki Kobori, Yoko Nishijima, Yuichiro Yano, Koji Sakata, Manabu Hayakawa, Akira Nishiyama
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Journal of Diabetes Research
Online Access:http://dx.doi.org/10.1155/2015/517472
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. The aims of this study were (1) to examine the renoprotective effects of alogliptin and (2) to establish urinary angiotensinogen (AGT) as a prognostic marker of renoprotective effects of alogliptin in patients with type 2 diabetes (T2D). Methods. In 43 patients with T2D (18 women, 66.1±1.71 years), 25 mg/day of alogliptin was added to the traditional hypoglycemic agents and/or nondrug treatments. Urinary concentrations of albumin (Alb) and AGT, normalized by urinary concentrations of creatinine (Cr) (UAlbCR and UAGTCR, respectively), were measured before and after the 12-week alogliptin treatment. Results. Alogliptin treatment tended to decrease UAlbCR (99.6±26.8 versus 114.6±36.0 mg/g Cr, P=0.198). Based on % change in UAlbCR, patients were divided into two groups, responders (<-25%) and nonresponders (≥-25%), and a logistic analysis of UAGTCR before treatment showed cutoff value of 20.8 µg/g Cr. When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n=20) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin (-14.6±8.6 versus +22.8±16.8%, P=0.033). Conclusion. Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.
ISSN:2314-6745
2314-6753